Lyell Immunopharma Inc

Innovative ROR1-targeting therapies, including zilovertamab vedotin and CS5001, show promise in cancer treatment. Zilovertamab vedotin achieved a 100% complete response rate in a Phase 2 trial for DLBCL. CS5001 demonstrated clinical activity in both solid tumors and lymphomas, with an overall ORR of 48.4%. These advancements highlight the potential of ROR1-targeted therapies in offering precise and effective cancer treatments.

IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy, showed 94% ORR and 71% CR in CAR T-naïve large B-cell lymphoma patients with manageable safety. No Grade 3+ CRS and low Grade 3 ICANS were reported, with rapid resolution using standard protocols. IMPT-314 demonstrated robust expansion and peak cell expansion between Days 7-28 post infusion, with a final product enriched for naïve and central memory T cells.

Lyell Immunopharma to present IMPT-314 Phase 1-2 data at ASH 2024 for aggressive B-cell lymphoma, a dual-targeting CD19/CD20 CAR T-cell therapy with Fast Track Designation.

Lyell Immunopharma to present initial IMPT-314 Phase 1-2 data at ASH 2024 for aggressive B-cell lymphoma. IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy, has FDA Fast Track Designation.